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In October 2011, the Advisory Com-mittee on Immunization Practices(ACIP) recommended hepatitis B vac-
cination for adults with diabetes in the
United States (1). Serosurvey data from
the 1999–2010 National Health and Nu-
trition Examination Survey found that
noninstitutionalized adults aged $18
years with diabetes have an increased se-
roprevalence of past or current hepatitis B
virus (HBV) infection (1). Outbreaks of
hepatitis B in elderly persons with diabe-
tes in long-term care facilities have been
linked to diabetes care procedures (in-
cluding blood glucose monitoring), with
likely vehicles for transmission including
spring-loaded finger-stick devices used
on multiple patients and blood glucose
testing meters that were not cleaned be-
tween uses on different patients.
In the U.S., hepatitis B vaccination is
routinely recommended for infants, chil-
dren, and adolescents. It also is recom-
mended for adults at increased risk of
HBV infection, including persons with
end-stage renal disease or chronic liver
disease, health care personnel, injection-
drug users, and men who have sex with
men (2–4). A hepatitis B vaccination se-
ries results in protection in a high propor-
tion (.95%) of infants, children, and
young adults (5). As with other vaccines,
the efficacy of the hepatitis B vaccine pro-
gressively declines with advancing age,
as well as with the presence of obesity
and other comorbid conditions (6–12).
Results of studies of the hepatitis B vac-
cine among persons with diabetes gener-
ally follow these patterns (13,14).
Primary hepatitis B vaccination usu-
ally consists of 3 (or 4) doses of 10 or
20 mg of recombinant hepatitis B surface
antigen (HBsAg) protein administered in-
tramuscularly into the deltoid muscle
on a 0-, 1-, and 6-month schedule
(Table 1). Alternative schedules are U.S.-
approved for routine vaccination for spe-
cific ages and vaccine formulations, and
they elicit dose-specific and final rates of
seroprotection similar to those obtained
on a 0-, 1-, and 6-month schedule (4).
Two single-antigen recombinant vac-
cines, Recombivax HB (Merck & Co,
Inc., Whitehouse Station, NJ) and
Engerix-B (GlaxoSmithKline Biologicals,
Rixensart, Belgium), and one combi-
nation hepatitis A/hepatitis B vaccine,
Twinrix (GlaxoSmithKline Biologicals),
are approved for use in adults in the U.S.
(15). Hepatitis B vaccines are safe for all
age groups. Administration of additional
vaccine doses for nonresponders is not
associated with an increase in adverse
events (16). Vaccination is not contrain-
dicated in persons with autoimmune or
chronic diseases, or in those who are
pregnant (4).
No review has been published of the
efficacy of the hepatitis B vaccine among
persons with diabetes; results of studies
among persons with diabetes show some
heterogeneity comparedwith adultswithout
diabetes. Differences in diabetes type, man-
agement, and glycemic control, as well as
vaccine, dosage, administration route, or
schedule, may underlie this heterogeneity.
The 2011 ACIP recommendation for hepa-
titis B vaccination for adultswithdiabetes, an
increasing incidence of diabetes, and the
high prevalence of diabetes among certain
groups recommended for hepatitis B vacci-
nation (e.g., persons with end-stage renal
disease) suggests that a review of vaccine ef-
ficacy among persons with diabetes may be
timely.We therefore performed a systematic
review of the literature and summarized the
evidence for seroprotection after hepatitis B




Electronic searches of MEDLINE (via
PubMed), EMBASE (via Ovid), Cochrane
Library, andWeb of Knowledge databases
were performed. The search terms con-
sisted of (hepatitis b vaccin* OR hbv vac-
cin* OR hepatitis b immuni* OR hbv
immuni*) AND (immunogeni* OR im-
mune response OR antibody) AND (dia-
betes). The search terms also were used as
Medical SubjectHeading terms (MEDLINE)
or key words (EMBASE), as applicable.
Where possible, limits included publica-
tion date from 1986 through 30 April
2012, English language, and study of hu-
mans. The MEDLINE and EMBASE
searches were limited to items containing
abstracts. Studies conducted in the U.S. and
other countries were eligible for inclusion.
Inclusion criteria
Peer-reviewed, published randomized
clinical trials or observational studies (all
types) assessing response to hepatitis B
vaccine among persons with type 1 or
type 2 diabetes were included. Studies
among both children and adults were in-
cluded to ascertain the effect of age upon
vaccine response among persons with
diabetes. Reports had to specify the pro-
portion (numerator and denominator) of
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subjects seroprotected by diabetes status
(or data available that allowed for calcula-
tion of the proportions), or available odds
ratios from a multivariate analysis, which
included diabetes as a predictor variable.
Studies of specific subject populations of
which persons with diabetes represented a
subset were included.
Exclusion criteria
Studies were excluded when immune
response using an antibody to hepatitis
B surface antigen (anti-HBs) threshold of
10 mIU/mL was not reported; immune
response was not measured between
0 and 6 months after the last vaccine
dose (because anti-HBs titers wane over
time); 10 or fewer subjects with diabetes
were included; vaccine was administered
intradermally; or subjects were not naïve
to the vaccine or had positive serology for
HBsAg, anti-HBs, or antibody to hepatitis
B core antigen, indicating past or current
hepatitis B infection. When two studies
reported results for duplicate subjects,
one study was excluded. Studies were
not excluded when subjects received ad-
ditional vaccine dose(s) because they did
not achieve seroprotective concentrations
or when inclusion of a fraction of subjects
meeting an exclusion criterion was
deemed unlikely to affect the findings.
The determination as to inclusion or
exclusion was based on the above criteria
and was made irrespective of study
results.
Data extraction and categorization
Data were manually extracted and elec-
tronically recorded. Studies were classi-
fied into one of three subject categories:
adults (mean age .18 years), children
(mean age #18 years), and hemodialysis/
chronic kidney disease patients. Elements
for extraction included study charac-
teristics (e.g., study design, sample size,
publication year, country); subject charac-
teristics (e.g., age, diabetes type); vaccine
characteristics (e.g., vaccine, dosage,
route, schedule); and the proportion of
subjects attaining seroprotection, includ-
ing the time interval (in months) from the
last dose at which immune response was
measured. When vaccine or route of ad-
ministration differed by study arm, extrac-
tion elements were recorded for each arm
when possible.
An anti-HBs threshold of 10 mIU/mL
after series completion (an accepted
marker of immune protection) defined
seroprotection (4). When multiple im-
mune response measurements were re-
ported reflecting seroprotection at different
intervals during the primary vaccine se-
ries, the result after the final dose was re-
corded. When immune response was
measured more than once after vaccina-
tion, the result from the interval closest
to 1 to 2 months after the last dose (cor-
responding to the recommended interval
for postvaccination testing for serologic
response in the U.S. [4]) was recorded.
When immune response was measured
after a booster dose(s) or novel adjuvant
administration, results were recorded
separately and noted.
Odds ratios for attainment of sero-
protection were recorded for studies re-
porting results from a multiple logistic
regression model. When odds ratios and
95% CIs for the diabetes predictor vari-
able were reported for failure to achieve
seroprotection, the probability of attain-
ing seroprotection was calculated by tak-
ing the inverse of the reported values.
RESULTSdThe systematic electronic
search yielded 225 studies (53 from
MEDLINE, 105 from EMBASE, 20 from
Cochrane Library, and 47 from Web of
Knowledge; a list of these studies is avail-
able upon request). Of these 225 studies,
85 duplicates were identified. Abstracts
from the remaining 140 studies (62.2%)
were reviewed, and 94 (67.1%) were
deemed not relevant. Forty-six (32.9%)
full-text studies were retrieved and re-
viewed, and one additional duplicate was
identified (Fig. 1). Fifteen studies did not
fulfill inclusion criteria, and 13 met at
least one criterion for exclusion (Table 2
and Fig. 1), leaving 17 studies.
The 17 studies included 2 random-
ized clinical trials, 12 prospective, and 3
retrospective studies published between
1989 and 2012 (Table 3). The 17 studies
included 16,310 unique subjects, of
which approximately 9,286 had diabetes.
The subject categories consisted of adults
for 4 studies (285 subjects, of whom 152
had diabetes); children for 4 studies (472
subjects, of whom 206 had diabetes); and
hemodialysis/chronic kidney disease pa-
tients for 9 studies (15,553 subjects, of
whom approximately 8,928 had diabe-
tes). Subjects in the studies among adults
and children generally lacked comorbid-
ities (including kidney disease) other than
diabetes. One study among hemodialysis/
chronic kidney disease patients included
only subjects with chronic kidney disease
(i.e., no hemodialysis patients) (32), and
three studies included both hemodialysis
and chronic kidney disease patients
(36,42,44), one of which also included
peritoneal dialysis patients (44). The re-
mainder were comprised entirely of he-
modialysis patients. Seroprotection
against hepatitis B virus infection was as-
sessed in subjects by diabetes status in 16
studies (1,764 subjects, 633 with diabe-
tes). Five studies included diabetes in a
multivariate model (31,32,37,42,44).
No serious vaccine-related adverse event
was reported in any study.
The average age of subjects by study
ranged from 8.4 to 79.5 years. Diabetes
type was type 1 in five studies, type 2 in
one study, and type 1 and type 2 in two
studies. Diabetes type was not specified
in eight of the nine studies among
hemodialysis/chronic kidney disease pa-
tients; personswith type2diabetes constitute
more than half of persons with diabetes
starting dialysis in the U.S. (45). The vac-
cine type was exclusively recombinant in
15 studies, one of which used a combina-
tion hepatitis A/hepatitis B vaccine (43),
and was exclusively plasma derived in one
study; both recombinant and plasma-
derived vaccines were used in one study.
A novel adjuvant was administered to sub-
jects in two studies (40,41). Vaccine dos-
age ranged from 3 to 40 mg. Route of
Table 1dRecommended dosages of hepatitis B vaccine for adults aged >20 years* (4)
Single-antigen vaccine Combination vaccine













Adults 10 1 20 1 20 1
Adult hemodialysis patients and other
immunocompromised adults 40† 1 40‡ 2 NA NA
NA, not applicable. *Please refer to package insert. †Dialysis formulation administered on a 3-dose schedule
at 0, 1, and 6months. ‡Two1-mL doses administered in 1 or 2 injections on a 4-dose schedule at 0, 1, 2, and 6
months.
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administration was exclusively intramus-
cular in 15 studies and exclusively subcu-
taneous in one study; one study used
intramuscular or intradermal adminis-
tration routes in separate study arms.
The standard 0-, 1-, and 6-month sched-
ule was used exclusively or partially in
11 studies. Others were a 0-, 1-, 2-, and
12-month schedule and a 0-, 1-, 2-, and
6-month schedule (both U.S.-approved
alternatives), as well as a 0-, 1-, and
2-month schedule (not approved in the
U.S.). The sex distribution was generally
equivalent for most studies, although
men predominated in the studies among
hemodialysis/chronic kidney disease pa-
tients. The type of vaccine, dosage, route
of administration, schedule, and the inter-
val after the last dose when seroprotection
was assessed were equivalent for the dia-
betes and comparison groups except as
noted in Table 4.
Seroprotection proportions ranged
from 31.3–100.0% (median, 73.4%)
among persons with diabetes and
35.2–100.0% (median, 87.1%) for those
without diabetes. The proportion pro-
tected was generally greatest among
children, ranging from 54.2–100.0%
(median, 93.9%) among children with
diabetes and 98.0–100.0% (median
100.0%) among those without diabetes.
Among adults, seroprotection propor-
tions ranged from 31.3–94.4% (median,
88.2%) for those with diabetes com-
pared with 35.2–96.9% (median,
93.6%) for those without diabetes. Sero-
protection proportions were lowest for
hemodialysis/chronic kidney disease pa-
tients, ranging from 41.8–85.3% (me-
dian, 60.1%) for those with diabetes
and 61.8–87.5% (median, 75.1%) for
those without diabetes.
Seroprotection proportions among
subjects with diabetes were generally
lower when vaccine was administered
on a 0-, 1-, and 2-month schedule (not
approved in the U.S.) and greater when
vaccine was administered on a 0-, 1-, 2-,
and 12-month schedule (U.S.-approved
alternative schedule) compared with the
standard 0-, 1-, and 6-month schedule.
Two studies using a 0-, 1-, and 2-month
schedule reported relatively low seropro-
tection proportions for persons with di-
abetes in their corresponding subject
categories (54.2% among children [35]
and 45.8% among hemodialysis/chronic
kidney disease patients [34]), and two
studies using a 0-, 1-, 2-, and 12-month
schedule reported relatively high seropro-
tection proportions among subjects with
diabetes in their corresponding subject
categories (88.6% and 94.4% [13] among
adults and 66.7% among hemodialysis/
chronic kidney disease patients [33]).
When a fourth dose was administered to
children with diabetes after a primary se-
ries on a 0-, 1-, and 2-month schedule,
seroprotection increased from 54.2 to
100.0% in one study (35). Another study,
however, achieved an 88.2% seroprotec-
tion proportion when vaccinating adults
with diabetes subcutaneously using
a 0- , 1- , and 2-month schedule
with thymopentin as an adjuvant (41).
Thymopentin is a synthetic pentapeptide
with activity characteristic of the thymic
hormone thymopoietin and is not ap-
proved for use in the U.S. It has been
used to enhance interleukin 2 production
and function of macrophages (46).
Administration of additional hepatitis
B vaccine doses may improve immune
response among adults with diabetes.
Douvin et al. (13) reported seroprotective
anti-HBs levels in 91.5% of adult subjects
with diabetes compared with 75.0% as
reported by Bouter et al. (14). Subjects
in both studies received 20-mg dosages
of recombinant hepatitis B vaccine intra-
muscularly. Subjects in the study by
Douvin et al. were, on average, older
than those in the study by Bouter et al.
(mean age, 49.2 vs. 34.3 years). It is there-
fore reasonable that subjects from the
study by Douvin et al. would have re-
sponded more poorly than those from
the study by Bouter et al. because older
age (6–9,31,47) is associated with a decline
Figure 1dSearch results. *Articles that were not a peer-reviewed, published randomized clinical
trial or observational study were not double-counted (among articles that did not specify the
proportion [numerator and denominator] of subjects seroprotected by diabetes status [or data
available to allow the calculation of the proportions] or the odds ratio from a multivariate
analysis that included diabetes as a predictor variable) so that the total would equal 15. †The
number of articles does not total 13 because one article met two inclusion criteria.
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in response. However, differences in the
number of doses administered likely con-
tributed to higher seroprotective propor-
tions in the Douvin et al. study, in which
30 subjects (42.3%) receiving vaccine on a
0-, 1-, 2-, and 12-month schedule also
received a booster dose at month 4 (for
an anti-HBs titer ,10 mIU/mL, according
to the study protocol). Therefore these sub-
jects received five total doses, compared
with three total doses on a 0-, 1-, and
6-month schedule reported by Bouter et al.
Five studies among hemodialysis/
chronic kidney disease patients included
diabetes in a mult ivar iate model
(31,32,37,42,44) (Table 5). All studies
controlled for age, and three controlled
for obesity. Four studies, with a total of
587 subjects (186 with diabetes), reported
that diabetes was independently associated
with failure to achieve seroprotection
(odds ratio [OR] 0.23–0.50 [95% CI
0.09–0.96]) (31,32,42,44). In their study
of 14,546 predominantly hemodialysis
patients, Lacson et al. (37) reported no
decrease in seroprotection associated
with diabetes (OR 1.02 [95% CI 0.93–
1.12]), although a subanalysis of 814
pairs (including subjects with and with-
out diabetes) matched for age, sex, race,
dialysis vintage, and dialysis modality
reported a decrease in seroprotection as-
sociated with diabetes (OR 0.71 [95% CI
0.52–0.97]).
A lower seroprotection proportion
was achieved among children with di-
abetes who received the vaccine using
intradermal administration, which is not
a U.S.-approved route of administration.
Li Volti et al. (38) reported 77.8% sero-
protection with intradermal administra-
tion compared with 100.0% seroprotection
with intramuscular administration. Among
children without diabetes, 100.0% in
both intradermal and intramuscular
arms achieved seroprotection (38). Other
studies have found improved results with
intradermal administration of the hepatitis
B vaccine in dialysis patients (48).
Thymopentin or priming with teta-
nus toxoid (TT) was used in two studies
to enhance the immune response to the
hepatitis B vaccine. Thymopentin was
administered to adults with diabetes three
times per week for a week before hepatitis
B vaccination and for 3 weeks afterward.
The results were compared with hepatitis
B vaccination among normal control sub-
jects (41). TT was administered 2 days
before an additional dose of hepatitis B
vaccine to hemodialysis/chronic kidney
disease patients who were nonresponders
after 6 or 7 doses of hepatitis B vaccine
that had been administered during the
previous 18 months (40). Although dif-
ferences in route of administration and
number of booster doses administered
prevent comparison with other studies,
seroprotection was reported in 88.2%
of adults with diabetes who received the
thymopentin adjuvant and in 100.0% of
previously nonresponding hemodialysis/
chronic kidney disease patients with
diabetes who had received TT before vac-
cination. Subsequent meta-analysis of
studies using thymopentin adjuvant
with hepatitis B vaccine in end-stage renal
disease patients (with and without dia-
betes) found limited benefit from the ad-
dition of thymopentin to hepatitis B
schedules (46).
CONCLUSIONSdWhen hepatitis B
vaccination is performed in accordance
with standard administration procedures,
children and young adults with diabetes
Table 2dExclusion criteria as applicable for 13 studies
Authors (reference) Publication year Exclusion criteria
Ahishali et al. (17) 2008 #10 subjects with diabetes
Chow et al. (18) 2006 #10 subjects with diabetes
Eldesoky et al. (19) 2009 Immune response measured .6 months
after last dose
Elwell et al. (20) 2003 Immune response measured .6 months
after last dose
Halota et al. (21) 2002 Some subjects anti-HBc positive
Kramer et al. (22) 2009 Immune response threshold other
than 10 mIU/mL
Marseglia et al. (23) 2000 Immune response measured .6 months
after last dose, duplicate subjects from
Marseglia et al., 1996
Morais et al. (24) 2007 Vaccine administered ID
Pascasio et al. (25) 2008 Some subjects anti-HBc positive
Pozzilli et al. (26) 1987 Immune response threshold other
than 10 mIU/mL
Somboonsilp et al. (27) 2003 Vaccine administered ID
Tsouchnikas et al. (28) 2007 #10 subjects with diabetes
Wismans et al. (29) 1991 Duplicate subjects from Bouter
et al., 1992
Anti-HBc, antibody to hepatitis B core antigen (total or not specified); ID, intradermally.
Table 3dCharacteristics of included studies
Author(s) (reference) Publication year Country Study design N
Arslanoglu et al. (30) 2002 Turkey Prospective 150
Bouter et al. (14) 1992 Netherlands Prospective 64
Chin (31) 2003 U.S. Retrospective 97
DaRoza et al. (32) 2003 Canada Prospective 165
Douvin et al. (13) 1997 France RCT 71
Eardley et al. (33) 2002 U.K. Prospective 86
Fabrizi et al. (34) 1996 Italy Prospective 188
Fiçicioglu et al. (35) 1995 Turkey Prospective 41
Hashemi et al. (36) 2011 Iran Prospective 167
Lacson et al. (37) 2005 U.S. Retrospective 14,546
Li Volti et al. (38) 1998 Italy RCT 42
Marseglia et al. (39) 1996 Italy Prospective 239
Ocak et al. (40) 2008 Turkey Prospective 49
Pagani et al. (41) 1989 U.K. Prospective 64
Taheri et al. (42) 2005 Iran Prospective 125
Williams et al. (43) 2012 U.S. Prospective 86
Zitt et al. (44) 2012 Austria Retrospective 200
RCT, randomized clinical trial.
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generally have responses similar to per-
sons of comparable age without diabetes.
Older adults have a reduced response,
and older adults with diabetes seem to
have further impairment in vaccine re-
sponse, particularly those with coexisting
kidney conditions.
There are several hypotheses about
the biological basis for potentially im-
paired response to vaccination among
persons with diabetes. Although persons
with diabetes have appropriate humoral
immune responses to vaccination (49),
impaired cellular response may account
for less robust antibody production after
hepatitis B vaccination (14). Proposed ex-
planations include a reduction in the
number of circulating helper T cells, the
CD4-to-CD8 lymphocyte ratio, and lym-
phocyte blastogenesis (23) and defects
with antigen presentation (39). Impaired
vaccine response also has been linked to
the presence of DR3, DR7, and DQ2 hu-
man leukocyte antigen alleles among per-
sons with diabetes (13). However, no
association between seroprotection and
glycemic control (13,14,30,39), duration
of diabetes (13,30,39), insulin require-
ment (30,39), or microangiopathic com-
plications (39) was demonstrated in
studies included in this review.
Obesity is a major risk factor for type
2 diabetes; 53% of adults with diabetes
are obese (50). Studies have demon-
strated an association between obesity
and a reduced response to hepatitis B vac-
cine in adults (51). A needle length that is
inadequate to penetrate the deltoid fat
pad and reach the muscle mass may ac-
count for the reduced immune response
among persons with obesity (4,52). The
less abundant blood supply in adipose
tissue may delay antigen presentation to
the B and T cells responsible for the im-
mune response (52). However, the needle
should not be so long that it involves the
underlying bone (4).
In addition to obesity (52), older age
(6–9,47), comorbid conditions (11), and
medication use (12) have been associated
with impaired vaccine response and may
confound the relationship between diabe-
tes and immune response. Four multivari-
ate analyses among hemodialysis/chronic
kidney disease patients included in this
review, all of which controlled for age
and three of which controlled for obesity,
found diabetes to be an independent fac-
tor for impaired vaccine response
(31,32,42,44). Lacson et al. (37), however,
reported a null association with diabetes
and seroprotection among hemodialysis/
chronic kidney disease patients (N =
14,546; OR 1.02 [95% CI 0.93–1.12]) in
their principal multivariate analysis.
Administration of additional doses of
hepatitis B vaccine improves the propor-
tion of persons responding to it. Addi-
tional doses have not caused unusual
adverse reactions (16). It is recommended
that health care personnel at continuing
risk of hepatitis B exposure and infants
with perinatal hepatitis B exposure
repeat a primary series of hepatitis B vac-
cine if they are found to be nonresponsive
to the initial series (4,5). Among health
care personnel who did not respond
after a primary series, 67.6% mounted a
protective response up to three additional
doses (11). Data exclusively on revaccina-
tion of nonresponding persons with
diabetes are sparse. Although postvacci-
nation serology to determine responses
among adults with diabetes is not cost
effective (Centers for Disease Control
and Prevention, 2011, unpublished
data) and not recommended, using
schedules requiring four rather than three
doses or administering additional doses
of hepatitis B vaccine remains an option.
A longer interval between the final
two doses of the primary hepatitis B
vaccine series has been associated with
higher final anti-HBs levels in general (4).
Findings from this review suggest that a
longer interval between the final two
doses also is associated with increased se-
roprotection proportions among persons
with diabetes. Excessively long intervals
have the drawback of increasing the risk
for acquisition of HBV infection among
those with an incomplete series (4).
Other strategies that may augment the
response to hepatitis B vaccine in persons
with diabetes include the use of novel
adjuvants, higher dosages, or combination
vaccines. No hepatitis B vaccine with a
novel adjuvant is currently licensed for use
in theU.S. Recent prelicensure trials using a
two-dose schedule with a hepatitis B vac-
cine containing a toll-like receptor 9
(HBsAg-1018 ISS) agonist as the adjuvant
seems promising (53). Other strategies that
could be explored in clinical trials include
the use of the combined hepatitis A virus
and HBV vaccine Twinrix (GlaxoSmithK-
line Biologicals) (54,55) or hemodialysis
dosage of the hepatitis B vaccine (56). Be-
cause response declines with advancing age
and comorbidities (11), vaccination soon after
diabetes diagnosis likely would constitute the
most practicalway to optimize seroprotection.
This review has several limitations. It
is possible that all relevant studies may
not have been identified in the literature
search, especially those studies in which
Table 5dMultiple logistic regression model results for attainment of seroprotective response
Authors (references) Predictor variable Other variables in model Matching Odds ratio 95% CI
Chin (31) Diabetes Age, weight, initial nPCR – 0.29*† 0.11–0.77*
DaRoza et al. (32) Diabetes Age, sex, use of erythropoietin,
albumin level, hemoglobin level,
urea level, weight, GFR
– 0.27 0.10–0.71
Lacson et al. (37)‡ Diabetes Age, sex, race, vaccine type, albumin,
BSA, hemoglobin, vintage




Taheri et al. (42) Diabetes Age, sex, dialysis treatment – 0.23 0.09–0.59*
Zitt et al. (44) Diabetes Age, sex, modality, 25(OH)D,
VDRA treatment
– 0.50 0.26–0.96
25(OH)D, 25-hydroxyvitamin D; BSA, body surface area; GFR, glomerular filtration rate; nPCR, normalized protein catabolic rate; VDRA, vitamin D receptor ac-
tivator. *Inverse of values reported by author because reported valueswere for failure to achieve seroprotection response. †Diabetes was no longer significant when the
parameter for baseline serum albumin was added into the model. ‡Seroprotection response threshold of 10 mIU/mLwas confirmed by personal communication with
author. xAuthors performed amatched analysis on a subset of 814 pairs (for this subset analysis, matched variables were excluded frommultivariatemodel); odds ratio
and 95% CI from matched analysis were 0.71 and 0.52–0.97, respectively.
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persons with diabetes represented a sub-
set of the population. There is the poten-
tial for publication bias. Studies with
significant results are more likely to be
published than those with null results,
and this review consisted only of pub-
lished studies. A null result for some stud-
ies in this review would consist of an
equivalent vaccine response in persons
with and without diabetes. It is therefore
unlikely that publication bias would lead
to a reported overestimate of vaccine re-
sponse among persons with diabetes.
Only 17 of the identified studies were
included in this review (and only 5 mul-
tivariate analyses), and data pertaining
to adults with diabetes but without
hemodialysis/chronic kidney disease were
sparse.Observational studieswere included,
and the results of these studies may not be
as robust as randomized clinical trials. The
matched comparison groups and ob-
jective outcome measure (i.e., anti-HBs
levels) strengthen the data quality.
Outcomes consisted of serological corre-
lates of protection (anti-HBs levels),
which may not correlate with maintaining
full vaccine effectiveness over time. Im-
munocompetent persons found to have
anti-HBs levels of $10 IU/L after the pri-
mary series, consistent with the threshold
used by studies included in this review,
are considered to be protected (4,5,57).
Duration of protection was not assessed
in this review, although other evidence
suggests protection lasts for two decades
in healthy primary vaccine responders.
However, data on the duration of immune
memory in immunocompromised per-
sons are limited (4). Although general
conclusions were drawn from a synthesis
of the results, no attempt was made to
test for statistically significant differences.
A meta-regression was not conducted
because colinearity likely exists among
sources of heterogeneity (e.g., children
most likely have type 1 diabetes and are
treated with insulin). Heterogeneity be-
tween studies by diabetes type, manage-
ment, glycemic control, and vaccine type,
dosage, administration route, and sched-
ule limit synthesis of results.
High levels of seroprotection from
recombinant hepatitis B vaccine are
achieved safely in children with diabetes.
Data from studies reviewed here suggest
that adults with diabetes have a reduced
response to vaccination. Seroprotection
is decreased among older adults and per-
sons on hemodialysis in general, including
those with diabetes. Administration of
schedules using an extended interval to
the final dose, four vs. three doses, or
additional vaccine doses may achieve
seroprotection in a greater proportion of
adults with diabetes, including those who
do not respond to an initial series. Other
strategies to increase response among
older adults with diabetes, including those
with other comorbid conditions, should
be explored.
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